New drug trial targets deadly prostate cancer variant
NCT ID NCT07218666
Summary
This study is testing an experimental pill called zanzalintinib for men with a particularly aggressive and difficult-to-treat form of advanced prostate cancer that has spread. The main goal is to see if the drug can slow or stop the cancer's growth and improve survival. About 30 men who have already tried standard hormone-blocking treatments will take the pill daily to see how well they respond and how safe the treatment is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE VARIANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.